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Abstract
The peptides angiotensin IV and LVV-hemorphin 7 were found to enhance memory in a number of
memory tasks and reverse the performance deficits in animals with experimentally induced
memory loss. These peptides bound specifically to the enzyme insulin-regulated aminopeptidase
(IRAP), which is proposed to be the site in the brain that mediates the memory effects of these
peptides. However, the mechanism of action is still unknown but may involve inhibition of the
aminopeptidase activity of IRAP, since both angiotensin IV and LVV-hemorphin 7 are competitive
inhibitors of the enzyme. IRAP also has another functional domain that is thought to regulate the
trafficking of the insulin-responsive glucose transporter GLUT4, thereby influencing glucose uptake
into cells. Although the exact mechanism by which the peptides enhance memory is yet to be
elucidated, IRAP still represents a promising target for the development of a new class of cognitive
enhancing agents.
Background
The incidence of age-related neurological diseases is esca-
lating due primarily to the increased life expectancy in the
general population of many developed nations. One of
the more prevalent and debilitating neurological disor-
ders is Alzheimer's disease (AD). The widely accepted
'amyloid hypothesis' of AD has resulted in drug develop-
ment strategies focused on the modulation of the amy-
loid-β (Aβ) processing enzymes (β and γ secretases) and
prevention of Aβ aggregation or oligomerization (vaccine
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for Aβ) [1]. The role of hyperphosphorylated tau protein
has recently gained prominence and some new interven-
tion therapies have focussed on the 'responsible' kinases,
including glycogen synthase kinase 3β and cyclin-depend-
ent kinase [1]. The quandary with these disease-modifying
approaches is that the etiology of AD is still not well
understood. Although the disease is characterized by the
deposition of amyloid plaques, and neurofibrillary tan-
gles, it is not known if these pathological hallmarks play
causative, in addition to indicative, roles.
Currently, all drugs approved by the Food and Drug
Administration (FDA) for AD address its symptoms. Most
belong to the class of cholinesterase inhibitors, are of lim-
ited efficacy [2], and are indicated for the treatment of
mild-to-moderate forms of the disease [3]. In spite of this,
many drugs currently being developed to treat cognitive
decline in AD are still targeting central cholinergic systems
http://www.alzforum.org/drg/drc. These include the new
generation cholinesterase inhibitors, cholinergic receptor
agonists, and drugs that facilitate cholinergic transmis-
sion. The exception is the NMDA receptor antagonist
memantine, which works to prevent excitotoxicity and
cell death, and is the only medication that has been
approved in the European Union, Australia, and by the
FDA, for the treatment of moderate-to-severe AD. It is cur-
rently not approved for the treatment of early AD, as its
efficacy has not as yet been substantiated for mild-to-
moderate AD [4]. More innovative approaches are
required in the development of symptomatic treatments.
This has recently been realised in the form of ampakines
and modulators of the CREB pathway [5]. Development
of memory-enhancing drugs is gaining momentum
because of their increasingly widespread application in
the treatment of other forms of memory disorders, includ-
ing mild cognitive impairment, as well as that resulting
from brain trauma and ischemic damage.
Rationale for proposing that insulin-regulated 
aminopeptidase is a novel target for the 
development of cognitive enhancers
Our discovery that peptide inhibitors of insulin-regulated
aminopeptidase (IRAP) elicit significant effects on mem-
ory acquisition and retrieval provides the basis for the
proposition that IRAP is a novel target for the discovery of
cognitive enhancers. Central administration of the two
peptides angiotensin (Ang) IV (Ang IV) or LVV-hemor-
phin 7 (LVV-H7) results in facilitation of memory, as
demonstrated in the conditioned and passive avoidance
paradigm [6-8], and enhanced performance in the spatial
memory tasks, as in the swim and Barnes mazes [9,10].
More importantly, these peptides reverse performance
deficits induced by global ischemia [11], bilateral per-
forant pathway lesion [9], perturbations of central cholin-
ergic systems [12-15], and chronic alcohol exposure [16].
At the cellular level, Ang IV has been shown to facilitate
long-term potentiation in the dentate gyrus of rats in vivo
[17] and in the CA1 region of the hippocampus in vitro
[18]. In view of the fact that long-term potentiation is con-
sidered to be a cellular marker for memory formation,
these findings provide further evidence that Ang IV does
indeed play a role in memory processing.
In 2001, the specific target for Ang IV and LVV-H7 was
identified – these peptides bind specifically, and with
high affinity, to the transmembrane aminopeptidase IRAP
[19]. Furthermore, Ang IV and LVV-H7 were found to be
competitive inhibitors of IRAP, inhibiting its aminopepti-
dase activity by binding to the catalytic site [20,21]. We
therefore propose that these peptides mediate their effects
on memory by binding to IRAP in specific brain nuclei. In
support of this hypothesis, IRAP is found in high concen-
trations in areas of the brain that are important for mem-
ory processing, including the hippocampus, amygdala,
and prefrontal cortex [22-24].
Target validation – characterization of the IRAP 
knockout mouse
Studies on the global IRAP knockout mouse revealed an
important proof-of-concept: that IRAP is the specific bind-
ing site in the brain for the peptide IRAP inhibitors, Ang
IV and LVV-H7. In the absence of IRAP expression, there
is a complete loss of the Ang IV binding site in the brain.
Preliminary studies demonstrated that the IRAP knockout
mice performed better than their wild-type littermates in
the swim maze [25]. However improvements in perform-
ances were not detected with other memory paradigms
including the novel object recognition and the spontane-
ous alternation T maze. In fact, an age-related deficit was
detected in the 6-month-old IRAP knockout mice in the Y
maze paradigm (Albiston, personal communication).
Although the mechanism via which Ang IV and LVV-H7,
by binding to IRAP, facilitate memory acquisition and
retrieval is not fully understood, it is irrefutable that these
peptides enhance memory and are specific, high affinity
inhibitors of IRAP. There is now sufficient evidence to
support the use of IRAP as a target for the identification of
a new class of cognitive enhancers.
Intracellular 'trafficking' domain of IRAP
IRAP was first identified as a protein that accompanies the
insulin-responsive glucose transporter GLUT4 within spe-
cialized vesicular compartments of fat and muscle cells
[26]. The movement of these GLUT4/IRAP-containing
vesicles to the plasma membrane is under the tight con-
trol of insulin, which facilitates an up to ten-fold increase
in the uptake of glucose into the cell [27]. IRAP is the only
transmembrane enzyme of the M1 family of aminopepti-
dases that contains a large intracellular domain. In theBMC Neuroscience 2008, 9(Suppl 2):S14 http://www.biomedcentral.com/1471-2202/9/S2/S14
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specialized GLUT4 vesicles, this 109 amino acid amino-
terminal tail of IRAP projects into the cytoplasm (Figure
1). This intracellular domain contains two dileucine
motifs preceded by acidic regions, which are thought to
play important roles in vesicular trafficking. Injection of
this IRAP domain into fat cells results in the translocation
of GLUT4 vesicles to the plasma membrane [28]. Moreo-
ver, this domain has been shown to interact with several
cytoplasmic proteins, including AS160 [29,30], tankyrase
[31], acyl-coenzyme A dehydrogenase [32], FHOS, the 'so
called' formin homolog overexpressed in spleen [33], and
p115 [29,34]; some of these proteins are associated with
intracellular protein transport machinery. It is therefore
possible that the amino-terminal cytoplasmic tail of IRAP
plays a significant role in the retention or trafficking of
GLUT4-containing vesicles in insulin-responsive cells.
Extracellular catalytic domain of IRAP
IRAP is a type II membrane protein of 160 kDa and
belongs to the gluzincin family of aminopeptidases [26]
that includes aminopeptidase A [35], aminopeptidase N
[36], and leukotriene A4 hydrolase [37]. The large car-
boxy-terminal domain of IRAP contains the proteolytic
active site characteristic of the M1 aminopeptidase family
consisting of the Zn2+ binding motif, HEXXH-(18X)-E,
and an exopeptidase motif, GAMEN (Figure 1). Muta-
tional analysis of the active site of IRAP revealed classic
characteristics of an aminopeptidase with single residue
mutations of the Zn2+ binding motif resulting in complete
loss of activity [38]. Rudberg et al. [39] proposed in 2002
that the GAMEN sequence is a consensus motif for an
amino-terminal recognition site in zinc aminopeptidases
with the glutamate (E) residue acting as an anionic bind-
ing site for substrates. Mutational studies reveal that the
G428, A429 and N432 residues in IRAP are important for
binding of both peptide substrates and inhibitors [40].
In many cell types and under basal conditions, IRAP
occurs predominantly in vesicles resembling large, dense
core vesicles, where the intraluminal location of its cata-
lytic domain can facilitate the processing of precursor pep-
tide sequences. Upon stimulation by insulin in fat and
muscle cells [41], IRAP translocates to the plasma mem-
brane, presenting its catalytic domain to the extracellular
surface.
IRAP had also been cloned from a human placental cDNA
library (as oxytocinase), based on the capacity of IRAP to
readily cleave oxytocin in vitro [42]. The plasma level of
IRAP is increased during the later stages of pregnancy and
it is thought that this enzyme is involved in the regulation
of circulating oxytocin to prevent the onset of premature
labour [43]. Interestingly, IRAP cleaves the first three resi-
dues from the amino terminus of a structurally related
peptide hormone, arginine-vasopressin, more efficiently
than oxytocin. There is current debate as to which peptide
is the more relevant, endogenous substrate of IRAP. Find-
ings from the IRAP knockout mice favour vasopressin
[44], whereas in the female reproductive system, oxytocin
appears more physiologically relevant [42]. Other in vitro
peptide substrates include somatostatin, lys-bradykinin,
met-enkephalin, dynorphin A, neurokinin A, neuromedin
B, and cholecystokinin 1–8 [21,45,46].
Development of inhibitors of IRAP as cognitive 
enhancers
Although IRAP was cloned more than a decade ago, the
first and only specific, high affinity inhibitors of IRAP that
Predicted domain structure of insulin-regulated aminopeptidase with key features highlighted Figure 1
Predicted domain structure of insulin-regulated aminopeptidase with key features highlighted.BMC Neuroscience 2008, 9(Suppl 2):S14 http://www.biomedcentral.com/1471-2202/9/S2/S14
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are used to investigate the physiological roles of the
enzyme are the peptides Ang IV and LVV-H7. However,
these peptides are not the ideal pharmacological tools, in
particular Ang IV, which is unstable in the circulation,
having a half-life of only seconds. In spite of their robust
memory-enhancing properties in rodents, these peptides
are unlikely to be useful for human therapy unless the
problems of oral bioavailability, stability and blood brain
barrier permeation can be overcome. Some attempts have
been made to design small molecule peptidomimetic
compounds based predominantly on the structure of Ang
IV (see below).
Peptide inhibitors of IRAP
The two archetypal competitive inhibitors of IRAP are the
peptides Ang IV (VYIHPF) and LVV-H7 (LVVYPWTQRF),
with Ki values of 113 nM and 845 nM, respectively [21].
The majority of structure-activity data has focussed on
sequence truncation or residue replacement of those two
peptides. The literature surrounding the activity of Ang IV
analogues, with respect to building structure-activity rela-
tionships, is somewhat confused by the historic contro-
versy over the macromolecular target. There are separate
but overlapping collections of data that assess either com-
petition binding to membrane fractions, or inhibition of
IRAP catalytic activity; there is clear evidence that these
two measures do not correlate. The significant factor
appears to be the presence (or absence) of zinc at the cat-
alytic site in the different assays, which contributes to sub-
strate and inhibitor affinity. The presence of metal ions in
tissue preparations can also confound binding data due to
the degradation of the test peptides by metalloproteases.
That said, there does appear to be some overlap in the gen-
eral descriptors of binding and enzyme inhibition that
might be utilized in future design. Suffice it to say, com-
pounds unable to bind IRAP fail to inhibit its activity.
Design of inhibitors of IRAP based on the known 
peptide inhibitors
The available data relating to inhibition of IRAP (summa-
rized in Table 1) point to a primary pharmacophore cen-
tred on the VYI/VYP motifs of the parent peptides.
Modulation of affinity is achieved by additional substitu-
ents, particularly on the carboxy-terminal side of the
tripeptide [47-49] (Figure 2). Several groups have looked
at structural modification by variation of the peptide
amide backbone. Divalinal-Ang IV was initially described
as an AT4-receptor antagonist, but displays an IRAP inhib-
itory property, albeit with lower affinity to Ang IV. A
group of non-peptide tyrosine derivatives (Figure 2) dis-
play structural similarities to the Ang IV tripeptide, and
have been described in the patent literature as potent AT4
receptor agonists [50]. Unfortunately, no data are availa-
ble describing IRAP inhibition of these compounds. One
potential outcome of these structural changes is stabiliza-
tion against peptidase activity, an important criterion in
developing effective therapeutics. Introduction of modi-
fied amino acids can also achieve this goal, and replace-
ment of the amino-terminal valine with β2-homovaline,
reportedly stabilizes the analogue relative to the parent
while maintaining inhibitory potency [51].
Little has been attempted to date with respect to learning
the conformational requirements for enzyme inhibitory
activity of either Ang IV or LVV-H7. Fledgling attempts
have been described that utilize peptide cyclization to sta-
bilize specific conformational populations of Ang IV, and
the results would appear quite encouraging [49]. For
example, the use of cystine or homocystine disulfide link-
Table 1: Summary of inhibitiory constants for angiotensin IV and LVV-hemorphin 7 and their analogues for IRAP
Reference Ki (nM) *
Angiotensin IV and analogues
Val-Tyr-Ile-His-Pro-Phe [21] 113
Nle-Tyr-Ile-His-Pro-Phe [21] 340
Val-Tyr-Ile-Cys-Pro-Cys [49] 25.8†
Val-Tyr-Ile-[AMPAA] [49] 43.6†
Valψ(CH2NH2)-Tyr-Valψ(CH2NH2)-His-Pro-Phe (divalinal-AT4) [21] 2300
β2hVal-Tyr-Ile-His-Pro-Phe [51] 26‡
LVV-hemorphin 7 and analogues
Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe [48] 196
Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe [21] 845
Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe [48] 56
Leu-Val-Val-Tyr-Pro-Trp-Thr [48] 560
Val-Tyr-Pro-Trp-Thr [48] 112
Val-Tyr-Pro [48] 620
*Data obtained using HEK293 cells transiently transfected with insulin-regulated aminopeptidase and L-Leu-pNA as substrate. †Comparative 
angiotensin IV Ki data not reported. ‡Angiotensin IV Ki reported as 56 nM in this assay.BMC Neuroscience 2008, 9(Suppl 2):S14 http://www.biomedcentral.com/1471-2202/9/S2/S14
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ages as replacements for pairs of residues at both the
amino- and carboxy-terminal regions of Ang IV, have
yielded analogues that compete in binding, and in the lat-
ter case, inhibit enzyme activity. The use of conforma-
tional constraint, particularly around the key tripeptide
motif, would seem a potentially fruitful avenue to
improving potency, reducing susceptibility to other pepti-
dases, and possibly facilitating central nervous system
penetration. The tyrosine residue has been resistant to any
structural perturbation to date however. The successful
incorporation of conformational constraints, and subse-
quent conformational analyses, would allow the develop-
ment of a three-dimensional pharmacophore, expediting
the drug design process.
In summary, a body of data is emerging that offers the
promise of turning the peptide lead Ang IV into a small
molecule peptidomimetic, and developing a refined
understanding of the ligand/enzyme interactions that
must be maintained for inhibitory potency.
In silico-derived IRAP inhibitors
Alternative approaches include a large scale screening of
compound libraries using IRAP as the target to identify
novel, small molecule inhibitors of the enzyme. The fluor-
ometric assay to monitor the catalytic activity of IRAP is
readily adaptable for high throughput. The enzyme kinet-
ics and mutational studies have provided some, albeit
limited, understanding of the enzyme-inhibitor and
enzyme-substrate interactions [21,38,40], which is
required to enable the more cost- and time-effective com-
putational screening approach to drug discovery. In this
method, the structures of millions of commercially avail-
able compounds are docked into a three-dimensional
atomic model of the active site of IRAP, one at a time,
using powerful computing clusters. A binding score is cal-
culated and the compounds are ranked in the order in
which they are predicted to perform. The compounds are
then assayed for inhibitory activity.
The crystal structure of IRAP has not yet been solved.
However, the structure of a close family member, leukot-
riene A4 hydrolase, was published a few years ago [52]
and has been used to generate a homology model of the
catalytic domain of IRAP (residues L140 to S533; Figure
3). Both IRAP and leukotriene A4 hydrolase belong to the
M1 aminopeptidase family, and while the overall identity
between the sequences is low, the region immediately sur-
rounding the active site residues, including the region of
HEXXH and GAMEN motifs, is highly conserved (41%
Chemical structures of angiotensin IV and reported peptidomimetic analogues Figure 2
Chemical structures of angiotensin IV and reported peptidomimetic analogues.
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identity). The central catalytic domain is structurally con-
served across a wide-range of zinc-dependent peptidases.
For example, although Thermoplasma acidophilum Tricorn
Interacting Factor F3 has only 16% identity with leukot-
riene A4 hydrolase at the amino acid level, the catalytic
domains are structurally similar based on a comparison of
their crystal structures with a root-mean-square deviation
on 395 alpha-carbon atoms of 2.1 Å [52].
This molecular model of IRAP has been used to screen a
compound database containing 1.5 million compounds
assembled from commercially available libraries with fil-
ters to exclude compounds on the basis of poor pharma-
cokinetic properties and presence of highly reactive
moieties. Iterative screens based on the shape or structure
of the most potent 'hits' led to the identification of a fam-
ily of small molecule IRAP inhibitors [53,54]. These com-
pounds act as competitive inhibitors and do have
memory enhancing properties in rodents.
Conclusion
The fundamental discovery of peptide inhibitors of IRAP
and their ability to enhance memory underpins this
research. The utilization of a range of strategies will enable
the successful identification and development of new
IRAP inhibitors with potentially therapeutic applications
for the treatment of memory loss in AD.
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